Literature DB >> 17018334

Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.

Carolina García-Martínez1, Asia Fernández-Carvajal, Belen Valenzuela, Ana Gomis, Wim Van Den Nest, Stefano Ferroni, Cristina Carreño, Carlos Belmonte, Antonio Ferrer-Montiel.   

Abstract

UNLABELLED: Vanilloid receptor subunit 1 (TRPV1) is an integrator of physical and chemical stimuli in the peripheral nervous system. This receptor plays a key role in the pathophysiology of inflammatory pain. Thus, the identification of receptor antagonists with analgesic and anti-inflammatory activity in vivo is an important goal of current neuropharmacology. Here, we report that [L-arginyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl) glycinamide (H-Arg-15-15C) is a channel blocker that abrogates capsaicin and pH-evoked TRPV1 channel activity with submicromolar activity. Compound H-Arg-15-15C preferentially inhibits TRPV1, showing marginal block of other neuronal receptors. Compound H-Arg-15-15C acts as a noncompetitive capsaicin antagonist with modest voltage-dependent blockade activity. The compound inhibited capsaicin-evoked nerve activity in afferent fibers without affecting mechanically activated activity. Notably, administration of compound H-Arg-15-15C prevented the irritant activity of a local administration of capsaicin and formalin and reversed the thermal hyperalgesia evoked by injection of complete Freund's adjuvant. Furthermore, it attenuated carrageenan-induced paw inflammation. Compound H-Arg-15-15C specifically decreased inflammatory conditions without affecting normal nociception. Taken together, these findings demonstrate that compound H-Arg-15-15C is a channel blocker of TRPV1 with analgesic and anti-inflammatory activity in vivo at clinically useful doses and substantiate the tenet that TRPV1 plays an important role in the etiology of chronic inflammatory pain. PERSPECTIVE: This study reports the design of a potent TRPV1 noncompetitive antagonist that exhibits anti-inflammatory and analgesic activity in preclinical models of acute and chronic pain. This compound is a lead for analgesic drug development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018334     DOI: 10.1016/j.jpain.2006.03.008

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  8 in total

1.  Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1).

Authors:  Yaroslav A Andreev; Sergey A Kozlov; Sergey G Koshelev; Ekaterina A Ivanova; Margarita M Monastyrnaya; Emma P Kozlovskaya; Eugene V Grishin
Journal:  J Biol Chem       Date:  2008-06-25       Impact factor: 5.157

2.  Solid-phase synthesis of a library of amphipatic hydantoins. Discovery of new hits for TRPV1 blockade.

Authors:  Guillermo Gerona-Navarro; Rosario González-Muñiz; Asia Fernández-Carvajal; José M González-Ros; Antonio Ferrer-Montiel; Cristina Carreño; Fernando Albericio; Miriam Royo
Journal:  ACS Comb Sci       Date:  2011-07-08       Impact factor: 3.784

Review 3.  Neuroplasticity of ascending and descending pathways after somatosensory system injury: reviewing knowledge to identify neuropathic pain therapeutic targets.

Authors:  P Boadas-Vaello; S Castany; J Homs; B Álvarez-Pérez; M Deulofeu; E Verdú
Journal:  Spinal Cord       Date:  2016-01-12       Impact factor: 2.772

4.  Pharmacological and functional properties of TRPM8 channels in prostate tumor cells.

Authors:  Maria Valero; Cruz Morenilla-Palao; Carlos Belmonte; Felix Viana
Journal:  Pflugers Arch       Date:  2010-11-05       Impact factor: 3.657

5.  TRPC channels and diacylglycerol dependent calcium signaling in rat sensory neurons.

Authors:  Michaela Kress; Johannes Karasek; Antonio V Ferrer-Montiel; Nadja Scherbakov; Rainer Viktor Haberberger
Journal:  Histochem Cell Biol       Date:  2008-07-29       Impact factor: 4.304

Review 6.  Acid-sensitive ion channels and receptors.

Authors:  Peter Holzer
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Modifying tetramethyl-nitrophenyl-imidazoline with amino acids: design, synthesis, and 3D-QSAR for improving inflammatory pain therapy.

Authors:  Xueyun Jiang; Yuji Wang; Haimei Zhu; Yaonan Wang; Ming Zhao; Shurui Zhao; Jianhui Wu; Shan Li; Shiqi Peng
Journal:  Drug Des Devel Ther       Date:  2015-04-22       Impact factor: 4.162

8.  TRPM8 ion channels differentially modulate proliferation and cell cycle distribution of normal and cancer prostate cells.

Authors:  María Ll Valero; Fernanda Mello de Queiroz; Walter Stühmer; Félix Viana; Luis A Pardo
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.